BioCentury
ARTICLE | Clinical News

TGR-1202: Phase I/II started

September 28, 2015 7:00 AM UTC

TG Therapeutics began an open-label, U.S. Phase I/II trial to evaluate oral TGR-1202, IV ublituximab ( TG-1101) and IV Keytruda pembrolizumab in about 12 patients. TG Therapeutics has exclusive, worl...